ROBERT J FLANAGAN
CIK 1251512 · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.60M
Companies
4
Total Filings
50
Lifetime Open-Market Net
-$12.64M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WPC | Director | 22,756 | $70.16 | $1.60M | $82.3K | 11 | 2026-07-02 |
| Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Director | 13,970 | — | — | -$13.73M | 26 | 2016-02-25 |
| MARTEK BIOSCIENCES CORP (MATK) Delisted | Director | 0 | — | — | $0 | 7 | 2011-02-25 |
| Castle Brands Inc (ROX) Delisted | Director | 638,287 | — | — | $1.00M | 4 | 2008-09-25 |
Recent Filings · Page 3 of 5
50 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-10-08 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$504.9K | EDGAR |
| 2014-09-25 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$480.2K | EDGAR |
| 2014-09-12 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$452.8K | EDGAR |
| 2014-08-29 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$435.0K | EDGAR |
| 2014-08-13 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$390.2K | EDGAR |
| 2014-07-31 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$409.6K | EDGAR |
| 2014-07-21 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$418.9K | EDGAR |
| 2014-07-02 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Sell (S) | −16,000 | -$424.1K | EDGAR |
| 2014-02-24 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Exer (M) | +1,326 | $0 | EDGAR |
| 2014-02-19 | Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.